|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 2 | Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes显示文摘AIM To establish the impact of portal hypertension(PH) on wait-list/post-transplant outcomes in patients with polycystic liver disease(PCLD) listed for liver transplantation. METHODS A retrospective single-centre case controlled study of consecutive patients listed for liver transplantation over 12 years was performed from our centre. PH in the PCLD cohort was defined by the one or more of following parameters:(1) presence of radiological or endoscopic documented varices from our own centre or the referral centre;(2) splenomegaly(> 11 cm) on radiology inabsence of splenic cysts accounting for increased imaging size;(3) thrombocytopenia(platelets < 150 × 109/L); or(4) ascites without radiological evidence of hepatic venous outflow obstruction from a single cyst. RESULTS Forty-seven PCLD patients(F: M = 42: 5) were listed for liver transplantation(LT)(single organ, n = 35; combined liver-kidney transplantation, n = 12) with 19 patients(40.4%) having PH. When comparing the PH group with non-PH group, the mean listing age(PH group, 50.6(6.4); non-PH group, 47.1(7.4) years; P = 0.101), median listing MELD(PH group, 12; non-PH group, 11; P = 0.422) median listing UKELD score(PH group, 48; non-PH group, 46; P = 0.344) and need for renal replacement therapy(P = 0.317) were similar. In the patients who underwent LT alone, there was no difference in the duration of ICU stay(PH, 3 d; non-PH, 2 d; P = 0.188), hospital stay length(PH, 9 d; non-PH, 10 d; P = 0.973), or frequency of renal replacement therapy(PH, 2/8; non-PH, 1/14; P = 0.121) in the immediate post-transplantation period. CONCLUSION Clinically apparent portal hypertension in patients with PCLD listed for liver transplantation does not appear to have a major impact on wait-list or peri-transplant morbidity. | Neil Rajoriya Dhiraj Tripathi Joanna A Leithead Bridget K Gunson Sophie Lord James W Ferguson Gideon M Hirschfield | 2016 | World Journal of Gastroenterology2016，22，45： | 2 |
| 3 | Postcardiopulmonary bypass hypoxemia: a prospective study on incidence, risk factors, and clinical significance显示文摘 | Gideon M Evgeny K | 2000 | J Cardiothorac Vasc Anesth2000，14，5： | 1 |
| 4 | C-rective protein:a criti-cal update显示文摘 | Mark B Gideon M | 2003 | Clin Invest2003，111，： | 1 |
| 5 | Response of ribbed panels to reverberant acoustic fields显示文摘 | GIDEON M | 1962 | the Journal of the Acoustical Society of America1962，34，6： | 1 |
| 6 | A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors 显示文摘 | Gideon M Blumenthal Joell J | 2014 | Oncotarget2014，5，18： | 1 |
| 7 | Gene expression profiling in lung tissues from mice exposed to cigarette smoke, lipopolysaccharide, or smoke plus lipopolysaccharide by inhalation显示文摘 | Meng Q R Gideon K M Harbo S J | 2006 | Inhal Toxicol2006，18，： | 1 |
| 8 | New oceanic proxies for paleoclimate显示文摘 | Gideon M H | 2002 | Earth and Planetary Science Letters2002，203，： | 1 |
| 9 | Transanal endoscopic microsurgery:experience with 75 rectal neoplasms显示文摘 | Dina LC David M Gideon G | | 0，，： | 1 |
| 10 | C-reactive protein:a critical update显示文摘 | Mark b pepys Gideon M Hirschfield | 2003 | J Clin Invest2003，111，： | 1 |
| 11 | The Effects of Low-Dose Simvastatin and Ezetimibe Compared to High-Dose Simvastatin Alone on Post-Fat Load Endothelial Function in Patients With Metabolic Syndrome: A Randomized Double-Blind Crossover Trial显示文摘 | Jobien K Olijhoek Gideon R Hajer Yolanda van der Graaf Geesje M Dallinga-Thie Frank L J Visseren | 2008 | Journal of Cardiovascular Pharmacology2008，，2： | 1 |
| 12 | Is CEO Pay in High-Technology Finns Related to Innovation? 显示文摘 | Balkin D B Gideon D M Gomez-Mejia L R | 2000 | The Academy of Management Journal2000，43，6： | 1 |
| 13 | Early Complex Societies in NE China: The Chifeng International Collaborative Archaeological Research Project显示文摘 | Linduff Katheryn M Robert D Drennan Gideon Shelach | 2002 | Journal of Field Archaeology2002，，12： | 1 |
| 14 | Economic development of groundwater in arid zones with applications to the Negev Desert,Israel显示文摘 | Jack B Abraham M Gideon O | 1994 | Management Science1994，40，3： | 1 |
| 15 | Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity显示文摘 | Gideon P John J Frech M | 1992 | Mol Cell Biol1992，12，5： | 1 |
| 16 | Synovial volume-a marker of disease severity in rheumatoid arthritis ? Quantification by MRI显示文摘 | Ostergaard M Gideon P Henrikseu O | 1994 | Scand J Rheumatol1994，23，4： | 1 |
| 17 | Synovial volume-a marker of disease severity in rheumatoid arthritis? Quantification by MRI显示文摘 | Ostergaard M Gideon P Henriksen O | 1994 | Seand J Rheumatol1994，23，4： | 1 |
| 18 | Erythropoietin in patients with aneurysmal subarachnoid haemorrhage:a double blind randomised clinical trial显示文摘 | Springborg JB M?ller C Gideon P | 2007 | Acta Neurochir(Wien)2007，149，11： | 1 |
| 19 | C-reactive protein: a critical update显示文摘 | Mark B Pepys Gideon M Hirschfield | 2003 | Clin Invest2003，111，12： | 1 |
| 20 | Boron removal by the duckweed Lemna gibba:A potential method for the remediation of boron-polluted waters显示文摘 | Claudia M Del-Campo Marina Gideon Oron | 2007 | Water Research2007，41，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员